T-PLL Incidence in 18 to 20 Months CD2-p13 Mice
| Transgenic Line . | Major Tumoral Load* . | Minor Tumoral Load-151 . | Small Cell Variants-152 . | T-PLL Free Mice . |
|---|---|---|---|---|
| F3 | 2/12 (17%) | 9/12 (75%) | 1/12 (8%) | 0/12 (0%) |
| F4 | 8/22 (36%) | 3/22 (14%) | 0/22 (0%) | 11/22 (50%) |
| F7 | 0/14 (0%) | 1/14 (7%) | 2/14 (14%) | 11/14 (79%) |
| Control | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) | 29/29 (100%) |
| Transgenic Line . | Major Tumoral Load* . | Minor Tumoral Load-151 . | Small Cell Variants-152 . | T-PLL Free Mice . |
|---|---|---|---|---|
| F3 | 2/12 (17%) | 9/12 (75%) | 1/12 (8%) | 0/12 (0%) |
| F4 | 8/22 (36%) | 3/22 (14%) | 0/22 (0%) | 11/22 (50%) |
| F7 | 0/14 (0%) | 1/14 (7%) | 2/14 (14%) | 11/14 (79%) |
| Control | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) | 29/29 (100%) |
*Major tumoral load as defined by more than 25% of clonal splenocytes estimated by Southern blotting and more than 60% of monomorphic cells in FACS analysis.
Minor tumoral load as defined by 10% to 25% of clonal splenocytes estimated by Southern blotting and no lymphocytosis or organomegaly.
Small cell variant as defined by 10% to 25% of clonal splenocytes estimated by Southern blotting, but no larger than normal CD8 or CD4 lymphocytes.